A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.

Inclusion Criteria:

• Are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current COVID-19 infection less than or equal to (≤)72 hours prior to randomization
• Are men or non-pregnant women
• Women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study
• Agree to the collection of nasopharyngeal swabs and venous blood

Exclusion Criteria:

• Require mechanical ventilation or anticipated impending need for mechanical ventilation
• Received convalescent COVID-19 plasma treatment prior to enrollment
• Were resident in a nursing home or long-term care facility immediately prior to current hospitalization
• Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product
• Have an oxygen saturation (SpO2) less than (<)88 percent (%) while breathing room air at rest at randomization.